Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer.

Cohen EN, Fouad TM, Lee BN, Arun BK, Liu D, Tin S, Gutierrez Barrera AM, Miura T, Kiyokawa I, Yamashita J, Alvarez RH, Valero V, Woodward WA, Shen Y, Ueno NT, Cristofanilli M, Reuben JM.

Breast Cancer Res Treat. 2019 Aug;176(3):545-556. doi: 10.1007/s10549-019-05258-0. Epub 2019 May 3.

PMID:
31054033
2.

Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center.

Fouad TM, Ueno NT, Yu RK, Ensor JE, Alvarez RH, Krishnamurthy S, Lucci A, Reuben JM, Yang W, Willey JS, Valero V, Bondy ML, Cristofinalli M, Shete S, Woodward WA, El-Zein R.

PLoS One. 2018 Sep 24;13(9):e0204372. doi: 10.1371/journal.pone.0204372. eCollection 2018.

3.

Reproductive performance of Bos indicus beef cows treated with different doses of equine chorionic gonadotropin at the end of a progesterone-estrogen based protocol for fixed-time artificial insemination.

Alvarez RH, Pugliesi G, Nogueira Natal FL, Rocha CC, Ataide Júnior GA, Ferreira Melo AJ, Otzuk IP, Alvarenga de Oliveira C, Humblot P.

Theriogenology. 2018 Sep 15;118:150-156. doi: 10.1016/j.theriogenology.2018.06.003. Epub 2018 Jun 8.

PMID:
29906665
4.

Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.

Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT.

JAMA Oncol. 2018 Sep 1;4(9):1207-1213. doi: 10.1001/jamaoncol.2018.1436.

5.

Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer.

Ding Q, Wang Y, Zuo Z, Gong Y, Krishnamurthy S, Li CW, Lai YJ, Wei W, Wang J, Manyam GC, Diao L, Zhang X, Lin F, Symmans WF, Sun L, Liu CG, Liu X, Debeb BG, Ueno NT, Harano K, Alvarez RH, Wu Y, Cristofanilli M, Huo L.

Hum Pathol. 2018 Jul;77:121-129. doi: 10.1016/j.humpath.2018.04.002. Epub 2018 Apr 22.

PMID:
29689244
6.

Development of CNS metastases and survival in patients with inflammatory breast cancer.

Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK.

Cancer. 2018 Jun 1;124(11):2299-2305. doi: 10.1002/cncr.31336. Epub 2018 Mar 26.

7.

Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer.

Alvarez RH, Bechara RI, Naughton MJ, Adachi JA, Reuben JM.

Oncologist. 2018 Jun;23(6):660-669. doi: 10.1634/theoncologist.2017-0343. Epub 2018 Feb 27. Review.

8.

Identification of frequent somatic mutations in inflammatory breast cancer.

Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH, Lucci A, Valero V, Reuben JM, Meric-Bernstam F, Ueno NT.

Breast Cancer Res Treat. 2017 Jun;163(2):263-272. doi: 10.1007/s10549-017-4165-0. Epub 2017 Feb 27.

PMID:
28243898
9.

Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.

Alexander A, Karakas C, Chen X, Carey JP, Yi M, Bondy M, Thompson P, Cheung KL, Ellis IO, Gong Y, Krishnamurthy S, Alvarez RH, Ueno NT, Hunt KK, Keyomarsi K.

Oncotarget. 2017 Feb 28;8(9):14897-14911. doi: 10.18632/oncotarget.14689.

10.

Cancer pain: a review of epidemiology, clinical quality and value impact.

Neufeld NJ, Elnahal SM, Alvarez RH.

Future Oncol. 2017 Apr;13(9):833-841. doi: 10.2217/fon-2016-0423. Epub 2016 Nov 23. Review.

PMID:
27875910
11.

Clinical outcomes based on multigene profiling in metastatic breast cancer patients.

Basho RK, de Melo Gagliato D, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F.

Oncotarget. 2016 Nov 22;7(47):76362-76373. doi: 10.18632/oncotarget.12987.

12.

Evaluating the Utility of a 'N-of-1' Precision Cancer Medicine Strategy: The Case for 'Time-to-Subsequent-Disease Progression'.

Markman M, Kramer K, Alvarez RH, Weiss GJ, Ahn E, Daneker GW.

Oncology. 2016;91(6):299-301. Epub 2016 Oct 6. Review.

PMID:
27705967
13.

Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer.

Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Tin S, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM.

Oncotarget. 2017 May 30;8(22):35656-35668. doi: 10.18632/oncotarget.10290.

14.

Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer.

Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Sanda T, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM.

J Cancer. 2016 Jun 3;7(9):1095-104. doi: 10.7150/jca.13098. eCollection 2016.

15.

Physical-chemical and biological characterization of different preparations of equine chorionic gonadotropin.

Alvarez RH, Natal FL, Ribela MT, de Almeida BE, de Oliveira JE, Bartolini P.

J Vet Sci. 2016 Dec 30;17(4):459-465. doi: 10.4142/jvs.2016.17.4.459.

16.

MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.

Huo L, Wang Y, Gong Y, Krishnamurthy S, Wang J, Diao L, Liu CG, Liu X, Lin F, Symmans WF, Wei W, Zhang X, Sun L, Alvarez RH, Ueno NT, Fouad TM, Harano K, Debeb BG, Wu Y, Reuben J, Cristofanilli M, Zuo Z.

Mod Pathol. 2016 Apr;29(4):330-46. doi: 10.1038/modpathol.2016.38. Epub 2016 Feb 26.

17.

High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.

Kogawa T, Fouad TM, Liu DD, Wu J, Shen Y, Masuda H, Fujii T, Chavez-MacGregor M, Alvarez RH, Hortobágyi GN, Valero V, Ueno NT.

Oncologist. 2016 Jan;21(1):21-7. doi: 10.1634/theoncologist.2015-0101. Epub 2015 Dec 9.

18.

Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients.

Niu J, Andres G, Kramer K, Kundranda MN, Alvarez RH, Klimant E, Parikh AR, Tan B, Staren ED, Markman M.

Onco Targets Ther. 2015 Nov 11;8:3323-8. doi: 10.2147/OTT.S92443. eCollection 2015.

19.

Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.

Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F.

Am J Clin Pathol. 2015 Nov;144(5):713-21. doi: 10.1309/AJCPWDEQYCYC92JQ.

PMID:
26486734
20.

Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.

Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT.

JAMA Oncol. 2015 Dec;1(9):1311-8. doi: 10.1001/jamaoncol.2015.3062. Review.

21.

Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.

Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT.

Breast Cancer Res Treat. 2015 Jul;152(2):417. doi: 10.1007/s10549-015-3477-1. No abstract available.

PMID:
26092296
22.

Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.

Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT.

Breast Cancer Res Treat. 2015 Jul;152(2):407-16. doi: 10.1007/s10549-015-3436-x. Epub 2015 May 29. Erratum in: Breast Cancer Res Treat. 2015 Jul;152(2):417.

23.

Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment.

Sevcikova K, Zhuang Z, Garcia-Manero G, Alvarez RH, Kantarjian HM, Mego M, Albarracin C, Tang G, Strom SS, Medeiros LJ, Hortobagyi GN, Reuben JM, Khoury JD.

Leukemia. 2016 Jan;30(1):242-7. doi: 10.1038/leu.2015.122. Epub 2015 May 15. No abstract available.

PMID:
25975189
24.

Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.

Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F.

Clin Breast Cancer. 2015 Oct;15(5):325-31. doi: 10.1016/j.clbc.2015.03.004. Epub 2015 Mar 24.

25.

Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer.

Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT.

J Cancer. 2015 Jan 22;6(4):310-8. doi: 10.7150/jca.10580. eCollection 2015.

26.

Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors.

Goswami RS, Patel KP, Singh RR, Meric-Bernstam F, Kopetz ES, Subbiah V, Alvarez RH, Davies MA, Jabbar KJ, Roy-Chowdhuri S, Lazar AJ, Medeiros LJ, Broaddus RR, Luthra R, Routbort MJ.

Clin Cancer Res. 2015 Jun 1;21(11):2644-51. doi: 10.1158/1078-0432.CCR-14-2391. Epub 2015 Feb 18.

27.

Circulating tumor cells in newly diagnosed inflammatory breast cancer.

Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, Andreopoulou E, Alvarez RH, Woodward WA, Hortobagyi GN, Cristofanilli M, Reuben JM.

Breast Cancer Res. 2015 Jan 9;17:2. doi: 10.1186/s13058-014-0507-6.

28.

Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer.

Mego M, Zuo Z, Gao H, Cohen EN, Giordano A, Tin S, Anfossi S, Jackson S, Woodward W, Ueno NT, Valero V, Alvarez RH, Hortobagyi GN, Khoury JD, Cristofanilli M, Reuben JM.

Thromb Haemost. 2015 Mar;113(3):593-8. doi: 10.1160/TH14-07-0597. Epub 2014 Nov 6.

PMID:
25373787
29.

Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination.

Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M.

Breast Cancer Res. 2014 Sep 16;16(5):440. doi: 10.1186/s13058-014-0440-8.

30.

Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation.

Takiar V, Akay CL, Stauder MC, Tereffe W, Alvarez RH, Hoffman KE, Perkins GH, Strom EA, Buchholz TA, Ueno NT, Babiera G, Woodward WA.

Springerplus. 2014 Mar 31;3:166. doi: 10.1186/2193-1801-3-166. eCollection 2014.

31.

Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer.

Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN, Woodward WA, Alvarez RH, Bedrosian I, Kuerer HM, Hunt KK, Huo L, Babiera GV.

Cancer. 2014 May 1;120(9):1319-28. doi: 10.1002/cncr.28550. Epub 2014 Feb 7.

32.

A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients.

Escalante CP, Meyers C, Reuben JM, Wang X, Qiao W, Manzullo E, Alvarez RH, Morrow PK, Gonzalez-Angulo AM, Wang XS, Mendoza T, Liu W, Holmes H, Hwang J, Pisters K, Overman M, Cleeland C.

Cancer J. 2014 Jan-Feb;20(1):8-14. doi: 10.1097/PPO.0000000000000018.

33.

High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer.

Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, Garza RJ, Debeb BG, Alvarez RH, Valero V, Hortobagyi GN, Calin GA, Ueno NT, Woodward WA, Reuben JM.

PLoS One. 2014 Jan 8;9(1):e83113. doi: 10.1371/journal.pone.0083113. eCollection 2014.

34.

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.

Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT.

Ann Oncol. 2014 Feb;25(2):384-91. doi: 10.1093/annonc/mdt525. Epub 2013 Dec 18.

35.

Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.

Andreopoulou E, Vigoda IS, Valero V, Hershman DL, Raptis G, Vahdat LT, Han HS, Wright JJ, Pellegrino CM, Cristofanilli M, Alvarez RH, Fehn K, Fineberg S, Sparano JA.

Breast Cancer Res Treat. 2013 Oct;141(3):429-35. doi: 10.1007/s10549-013-2704-x. Epub 2013 Sep 26.

36.

Locoregional interaction of ixabepilone (ixempra) after breast cancer radiation.

Takiar V, Strom EA, Baumann DP, Meric-Bernstam F, Alvarez RH, Gonzalez-Angulo AM.

Oncologist. 2013;18(3):265-70. doi: 10.1634/theoncologist.2012-0348. Epub 2013 Feb 12.

37.

Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer.

Alvarez RH, Hortobagyi GN.

Breast Cancer. 2013 Apr;20(2):103-10. doi: 10.1007/s12282-013-0446-6. Epub 2013 Feb 3. Review.

38.

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.

Cristofanilli M, Johnston SR, Manikhas A, Gomez HL, Gladkov O, Shao Z, Safina S, Blackwell KL, Alvarez RH, Rubin SD, Ranganathan S, Redhu S, Trudeau ME.

Breast Cancer Res Treat. 2013 Jan;137(2):471-82. doi: 10.1007/s10549-012-2369-x. Epub 2012 Dec 13.

39.

Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.

Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM.

Mol Cancer Ther. 2012 Nov;11(11):2526-34. doi: 10.1158/1535-7163.MCT-12-0460. Epub 2012 Sep 12.

40.

Metastasis in the breast mimicking inflammatory breast cancer.

Alvarez RH, Gong Y, Ueno NT, Alizadeh PA, Hortobagyi GN, Valero V.

J Clin Oncol. 2012 Aug 1;30(22):e202-6. doi: 10.1200/JCO.2011.40.2230. Epub 2012 Jun 25. No abstract available.

PMID:
22734030
41.

Inflammatory breast cancer: what we know and what we need to learn.

Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Hortobágyi GN, Ueno NT.

Oncologist. 2012;17(7):891-9. doi: 10.1634/theoncologist.2012-0039. Epub 2012 May 14. Review.

42.

Novel targeted agents for the treatment of advanced breast cancer.

de la Vega M, Díaz-Cantón E, Alvarez RH.

Future Med Chem. 2012 May;4(7):893-914. doi: 10.4155/fmc.12.45. Review.

PMID:
22571614
43.

Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs.

Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, Alvarez RH, Lucci A Jr, Ueno NT, Buchholz TA.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1381-6. doi: 10.1016/j.ijrobp.2011.10.040. Epub 2012 Jan 26.

PMID:
22284689
44.

Bevacizumab treatment for advanced breast cancer.

Alvarez RH, Guarneri V, Icli F, Johnston S, Khayat D, Loibl S, Martin M, Zielinski C, Conte P, Hortobagyi GN.

Oncologist. 2011;16(12):1684-97. doi: 10.1634/theoncologist.2011-0113. Epub 2011 Oct 5. Review.

45.

Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.

Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M.

Ann Oncol. 2012 May;23(5):1144-50. doi: 10.1093/annonc/mdr434. Epub 2011 Sep 28.

PMID:
21965473
46.

Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.

Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M.

Breast Cancer Res. 2011 Jun 15;13(3):R67. doi: 10.1186/bcr2907.

47.

Ixabepilone for the treatment of breast cancer.

Alvarez RH, Valero V, Hortobagyi GN.

Ann Med. 2011;43(6):477-86. doi: 10.3109/07853890.2011.579151. Epub 2011 May 17. Review.

PMID:
21585248
48.

Present and future evolution of advanced breast cancer therapy.

Alvarez RH.

Breast Cancer Res. 2010;12 Suppl 2:S1. doi: 10.1186/bcr2572. Epub 2010 Oct 22. Review.

49.

Primary systemic therapy for operable breast cancer patients: the need for the new generation of trial design.

Alvarez RH, Hortobagyi GN.

Breast Cancer Res Treat. 2010 Dec;124(3):701-5. doi: 10.1007/s10549-010-1212-5. Epub 2010 Oct 16. No abstract available.

PMID:
20953832
50.

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L.

J Clin Oncol. 2010 Oct 1;28(28):4316-23. doi: 10.1200/JCO.2009.27.2419. Epub 2010 Aug 30. Erratum in: J Clin Oncol. 2010 Nov 10;28(32):4868. J Clin Oncol. 2012 Feb 20;30(6):679.

PMID:
20805453

Supplemental Content

Loading ...
Support Center